Article

204 views
KEY POINTS YL Biologics announced the successful clinical outcome of YLB113- biosimilar version of Amgen’s blockbuster rheumatoid arthritis drug, Enbrel® ...
Authentic, Ad-free Reporting
High-quality, Exclusive Content
Original Market Research Reports
Original Resources & Databases
Global Surveys & Guidelines
Lowest Subscription Pricing

Healthcare News You Won't Read Elsewhere

Most up-to-date information, original and in-depth reviews, full-length exclusive market reports and forecasts, full-access to the smart knowledge base centres, useful resources and databases.

Access articles & resources worth up to $4000.

KEY POINTS YL Biologics announced the successful clinical outcome of YLB113- biosimilar version of Amgen’s blockbuster rheumatoid arthritis drug, Enbrel® ...

You have read of your 8 free articles this month.

Subscribe to
Medgenera All-Access

Enjoy unlimited access to all contents, resources, exclusive market research reports, databases, surveys and many more features by subscribing to Medgenera All-Access.

Access articles & resources worth up to US $4, 000 per month.

Authentic, Ad-free Reporting
High-quality, Exclusive Content
Original Market Research Reports
Original Resources & Databases
Global Surveys & Guidelines
Lowest Subscription Pricing

Healthcare News You Won't Read Elsewhere

Most up-to-date information, original and in-depth reviews, full-length exclusive market reports and forecasts, full-access to the smart knowledge base centres, useful resources and databases.

Access articles & resources worth up to $4000.

More in DRUG TRIAL


DRUG TRIAL

Roche’s New Drug Shows Better Results than Renowned Tamiflu in Flu Patients

Roche’s investigational flu drug, Xofluza® (baloxavir marboxil) has reduced the risk of complications in patients with flu in a late-stage clinical study. It is the first single-dose, oral drug being developed for flu with a novel mechanism of action in about the last 20 years.

DRUG TRIAL

This New Cancer Drug Signifies ‘No Return of a Rare Blood Cancer’

AstraZeneca’s promising blood cancer drug, moxetumomab pasudotox has shown tumor shrinkage in 75 percent patients with hairy cell leukemia- a rare and chronic form of blood cancer.

DRUG TRIAL

15 Promising New Cancer Drugs in Late-Stage Clinical Development (2018)

Read about the most promising oncology drug candidates present in the pharmaceutical companies’ pipeline in 2018. The potential drugs with novel mechanisms are in their late-stage of clinical development to treat diverse types of cancers.

BRIEFING

Novel EGFR Lung Cancer Drug, Dacomitinib Gains FDA Priority Review

The understanding of epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) has been evolved over years. TKIs are found ...

Most Popular


GROW

7 New Ideas to Start a Healthcare Business in India (2018)

Seven new #healthcare #business ideas in India in 2018. Which one would you prefer to pursue?

NEWLY PUBLISHED

Pharma Patents: Can India Reward Incremental Innovation?

Chandramouli Natarajan is an Associate Scientist, Ricon pharma LLC, Denville, USA. He has presented his opinion and views on the Pharmaceutical patents issues in India. This article is available for free to read and share.